Insmed (INSM) Financial Analysis & Valuation | Quarter Chart
Insmed (INSM)
INSMPrice: $104.74
Fair Value: 🔒
🔒score
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is... more
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients... more
Description
Shares
| Market Cap | $22.70B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | William H. Lewis |
| IPO Date | 2000-06-01 | CAGR | 0.67% |
| Employees | 1,271 | Website | www.insmed.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
INSM chart loading...
Fundamentals
Technicals
| Enterprise Value | $35.07B | P/E Ratio | -18.22 |
| Forward P/E | 757.94 | PEG Ratio | — |
| P/S Ratio | 28.03 | P/B Ratio | 32.4 |
| P/CF Ratio | -25.49 | P/FCF Ratio | -24.14 |
| EPS | $-5.75 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 115.09% | Gross Margin | 0.82% |
| Operating Margin | -1.38% | Profit Margin | -1.44% |
| ROE | -1.3% | ROA | -0.57% |
| ROCE | -0.66% | Current Ratio | 4.47 |
| Quick Ratio | 4.1 | Cash Ratio | 1.61 |
| Debt/Equity | 1.06 | Interest Coverage | -13.95 |
| Altman Z Score | 5.3 | Piotroski Score | 4 |